An emerging crisis of antibiotic resistance for microbial pathogens is alarming all the nations,
posing a global threat to human health. The production of the metallo-β-lactamase enzyme is the
most powerful strategy of bacteria to produce resistance. An efficient way to combat this global health
threat is the development of broad/non-specific type of metallo-β-lactamase inhibitors, which can inhibit
the different isoforms of the enzyme. Till date, there are no clinically active drugs against metallo-
β-lactamase. The lack of efficient drug molecules against MBLs carrying bacteria requires continuous
research efforts to overcome the problem of multidrug-resistance bacteria. The present review will
discuss the clinically potent molecules against different variants of B1 metallo-β-lactamase.